{
  "trial_id": "NCT00868192",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, performance status (GOG), prior chemotherapy regimens, prior radiotherapy, bone marrow function (ANC, platelets), creatinine clearance, hepatic function (bilirubin, AST, alkaline phosphatase), neurologic function (neuropathy), coagulation (PT, INR, PTT), presence of measurable disease, target lesion status, history of cardiovascular disease, history of hypertension, history of myocardial infarction, history of bleeding disorders, history of CNS disease, proteinuria status, pregnancy status, lactation status, history of other invasive malignancies, history of abdominal fistula or gastrointestinal perforation, history of bowel obstruction, life expectancy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Gynecologic Oncology Group (GOG) Performance Status",
          "performance status (GOG)"
        ],
        [
          "Prior number of chemotherapy regimens",
          "prior chemotherapy regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Stage",
        "Histology",
        "Tumor grade",
        "Pathologic diagnosis",
        "Platinum-free interval"
      ],
      "remaining_candidate_features": [
        "race",
        "prior radiotherapy",
        "bone marrow function (ANC, platelets)",
        "creatinine clearance",
        "hepatic function (bilirubin, AST, alkaline phosphatase)",
        "neurologic function (neuropathy)",
        "coagulation (PT, INR, PTT)",
        "presence of measurable disease",
        "target lesion status",
        "history of cardiovascular disease",
        "history of hypertension",
        "history of myocardial infarction",
        "history of bleeding disorders",
        "history of CNS disease",
        "proteinuria status",
        "pregnancy status",
        "lactation status",
        "history of other invasive malignancies",
        "history of abdominal fistula or gastrointestinal perforation",
        "history of bowel obstruction",
        "life expectancy"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, Performance Status, Prior Chemotherapy Regimens, Bone Marrow Function (ANC, Platelets), Creatinine Clearance, Hepatic Function (Bilirubin, AST, Alkaline Phosphatase), Neurologic Function (Neuropathy), Coagulation (PT, INR, PTT), ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Gynecologic Oncology Group (GOG) Performance Status",
          "Performance Status"
        ],
        [
          "Prior number of chemotherapy regimens",
          "Prior Chemotherapy Regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Stage",
        "Histology",
        "Tumor grade",
        "Pathologic diagnosis",
        "Platinum-free interval"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Bone Marrow Function (ANC, Platelets)",
        "Creatinine Clearance",
        "Hepatic Function (Bilirubin, AST, Alkaline Phosphatase)",
        "Neurologic Function (Neuropathy)",
        "Coagulation (PT, INR, PTT)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Performance Status, Prior Chemotherapy Regimens, Prior Radiotherapy, Platinum-free Interval, CA-125 Level, Measurable Disease, Target Lesions, Non-target Lesions, Prior Bevacizumab or Pemetrexed Therapy, Prior Taxane Therapy, Prior Hormonal Therapy, Prior Surgery, Prior Infection, Prior Cardiovascular Disease, Prior Bleeding Disorder, Prior Central Nervous System Disease, Prior Surgical Procedure, Proteinuria, Creatinine Clearance, Hepatic Function, Bone Marrow Function, Coagulation Function, Neurologic Function.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Gynecologic Oncology Group (GOG) Performance Status",
          "Performance Status"
        ],
        [
          "Prior number of chemotherapy regimens",
          "Prior Chemotherapy Regimens"
        ],
        [
          "Platinum-free interval",
          "Platinum-free Interval"
        ]
      ],
      "remaining_reference_features": [
        "Stage",
        "Histology",
        "Tumor grade",
        "Pathologic diagnosis"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Prior Radiotherapy",
        "CA-125 Level",
        "Measurable Disease",
        "Target Lesions",
        "Non-target Lesions",
        "Prior Bevacizumab or Pemetrexed Therapy",
        "Prior Taxane Therapy",
        "Prior Hormonal Therapy",
        "Prior Surgery",
        "Prior Infection",
        "Prior Cardiovascular Disease",
        "Prior Bleeding Disorder",
        "Prior Central Nervous System Disease",
        "Prior Surgical Procedure",
        "Proteinuria",
        "Creatinine Clearance",
        "Hepatic Function",
        "Bone Marrow Function",
        "Coagulation Function",
        "Neurologic Function"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "age, sex, race, ethnicity, GOG performance status, histologic subtype of ovarian or primary peritoneal carcinoma, number of prior chemotherapy regimens, time since last platinum-based chemotherapy, presence of measurable disease, presence of target lesions, serum CA-125 level, creatinine clearance, absolute neutrophil count, platelet count, bilirubin level, AST level, alkaline phosphatase level, neuropathy grade, prothrombin time, international normalized ratio, partial thromboplastin time.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Gynecologic Oncology Group (GOG) Performance Status",
          "GOG performance status"
        ],
        [
          "Histology",
          "histologic subtype of ovarian or primary peritoneal carcinoma"
        ],
        [
          "Prior number of chemotherapy regimens",
          "number of prior chemotherapy regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Stage",
        "Tumor grade",
        "Pathologic diagnosis",
        "Platinum-free interval"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "time since last platinum-based chemotherapy",
        "presence of measurable disease",
        "presence of target lesions",
        "serum CA-125 level",
        "creatinine clearance",
        "absolute neutrophil count",
        "platelet count",
        "bilirubin level",
        "AST level",
        "alkaline phosphatase level",
        "neuropathy grade",
        "prothrombin time",
        "international normalized ratio",
        "partial thromboplastin time"
      ]
    }
  }
}